The advent of targeted therapy with tyrosine kinase inhibitors (TKIs) directed against the epidermal growth factor receptor (EGFR) has led to dramatic improvements of response and progression-free survival (PFS) in patients with EGFR-mutated lung cancer. Here, EGFR is linked to lung carcinoma.